LONDON: OptiBiotix Health plc (AIM: OPTI), a UK-based life sciences company focused on microbiome modulation and healthy sugar alternatives, reported a 35% increase in annual revenue for the year ending Dec. 31, 2024, signaling a strong turnaround bolstered by international expansion and ecommerce growth.
Revenue rose to £870,000 from £644,000 in 2023, driven by increased ecommerce activity—Amazon sales surged 156%—and strategic market entries in India and the United States. Total orders received for the year reached £1.004 million.
CEO Stephen O’Hara credited the company’s sales and marketing investments for delivering multi-channel growth while diversifying its partner base. “Sales have continued to grow in 2025 and should accelerate as we see the full-year effects of our 2024 launches,” O’Hara said in a statement.
Key operational highlights included:
- Ecommerce revenues more than doubled to £387,000, with a 290% rise in subscriptions.
- A December 2024 product launch with India-based Morepen generated £171,000 in revenue.
- The company booked its first U.S. order with wellness brand Daily Nouri and launched LeanBiome in MuscleTech, a major sports nutrition label.
- Fixed operating costs declined to £1.605 million from £1.662 million.
- OptiBiotix ended 2024 with a £739,000 cash position and no debt.
The company also reported clearing significant inventory backlogs at Maxum and Cambridge Commodities, positioning it for more accurate revenue recognition moving forward.
Post-year developments show continued momentum. Orders in Q1 2025 surpassed those in the first half of 2024, and new launches included SlimBiome®-based products on Amazon India and in U.S. retail channels. A six-metric-ton order from Australian distributor Brenntag and a new partnership with a NASDAQ-listed company signaled further international traction.
A recently published study in the European Journal of Nutrition—conducted in partnership with a major U.S. weight management brand—explored SlimBiome’s effect on glycaemic control and insulin response.
In May 2025, OptiBiotix raised £750,000 through a successful placing to support its U.S. market expansion.
The company’s Annual General Meeting is scheduled for Aug. 6, 2025, at Walbrook PR in London. An investor presentation will also be held on July 3, 2025, via the Investor Meet Company platform.
O’Hara said the business is on track to achieve positive cash flow and sustained profitability as it scales across markets and consolidates operational efficiencies.